In urgent, high-stakes situations—like major bleeding or emergency surgery—how should clinicians assess coagulation in patients on factor Xa inhibitors? And more importantly, are we focusing on the right signal?

Join global experts as they explore:

• Why traditional assays (PT/aPTT, anti-Xa) often fall short in critical decision-making

• The role of functional testing in assessing true hemostatic potential

• How VMX-C001, a novel bypassing agent, challenges conventional approaches to reversal and monitoring

Be sure to read the VMX-C001 study discussed in the episode.

Tune in now and subscribe to Clot, Clot, Who’s There? for more expert conversations bridging science, practice, and global perspectives in thrombosis, hemostasis, and vascular medicine.

Chapters
00:00 Introduction & Clinical Challenge
02:54 Assessing Factor Xa Inhibitors in Urgent/Emergent Situations
05:29 Why Standard Assays Fall Short
09:38 Functional Testing: dPT & dRVVT
12:35 VMX-C001 & Future Directions

This episode was made possible through generous support from VarmX.